Start Your Search
Aya El Helali
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
P3.01-23 - Imaging Modalities for Surveillance and Follow-Up of Patient with Lung Cancer After Adjuvant Chemotherapy (ID 13201)
12:00 - 13:30 | Presenting Author(s): Aya El Helali
Non-small cell lung cancer (NSCLC) represents over 80% of lung tumours. If diagnosed early, treatment is surgical with curative intent. The addition of postoperative cisplatin-based chemotherapy has demonstrated a significant survival advantageand is generally accepted as a standard treatment in patients of good performance status.
Despite this, risk of relapse remains high and current ESMO (2017) guidance suggests ‘NSCLC patients treated with radical intent should be followed for treatment-related complications, detection of treatable relapse or occurrence of second primary lung cancer. Recommendations for surveillance, include regular review, physical exam and imaging. This should be tailored to suitability of individual patients for further intervention. Local practice mandates a chest x-ray (CXR) with CT and/or PET follow-up of anomalies.a9ded1e5ce5d75814730bb4caaf49419 Method
Between January 2004 and May 2017 165 patients underwent surgical resection for Stage 1B-IIIA NSCLC. We identified all patients within this cohort with radiological evidence of thoracic recurrence who had relapsed following postoperative chemotherapy. Electronic patient care records were used for data collection. Patient characteristics, surveillance modalities and overall survival (OS) from date of diagnosis to first relapse were analysed. Imaging modalities detecting recurrence and OS were determined using Kaplan-Meier methodology (SPSS).4c3880bb027f159e801041b1021e88e8 Result
89 patients were identified, the median age was 62 years (range 42-77 years). Patients underwent surveillance initially every 3 months following completion of postoperative chemotherapy. Median time to relapse was 25.6 months (range 0.53 to 50.9 months). 62 patients (69.7%) had radiological confirmed evidence of disease recurrence. 4 (6.5%) had relapsed with extra-thoracic recurrence. 28 patients (45.2%) had confirmed intra thoracic disease recurrence on CXR despite chest CT imaging performed at designated time intervals. However, 27 patients (43.5%) that underwent surveillance with CXR had confirmed intra thoracic disease recurrence with chest CT imaging. Median OS for CXR detected recurrence was 27.5 months (range 6.5 – 99.1 months) and 27.45 months (range 5.9 to 104.2 months) for chest CT detected recurrence (p-value 0.46).8eea62084ca7e541d918e823422bd82e Conclusion
There is a paucity evidence specifically around the follow-up and surveillance modalities aimed at detecting relapse to improve survival after curative intent therapy in NSCLC.Our data demonstrate that 3 monthly CXR is an appropriate surveillance modality for initial detection of intra-thoracic disease recurrence.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.